Qiagen (NYSE:QGEN) Shares Sold by Nebula Research & Development LLC

Nebula Research & Development LLC cut its stake in Qiagen (NYSE:QGEN) by 9.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,276 shares of the company’s stock after selling 4,853 shares during the period. Nebula Research & Development LLC’s holdings in Qiagen were worth $1,972,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Barclays PLC increased its holdings in shares of Qiagen by 170.6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock valued at $84,259,000 after purchasing an additional 1,165,594 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Qiagen in the 3rd quarter worth approximately $53,000. Tidal Investments LLC purchased a new position in Qiagen during the 3rd quarter worth approximately $490,000. JPMorgan Chase & Co. raised its position in Qiagen by 36.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock worth $73,096,000 after buying an additional 424,937 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Qiagen by 170.1% during the 4th quarter. GAMMA Investing LLC now owns 1,518 shares of the company’s stock valued at $68,000 after acquiring an additional 956 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on QGEN shares. Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a report on Friday, April 4th. Morgan Stanley reissued an “equal weight” rating and issued a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Baird R W downgraded Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Robert W. Baird boosted their price target on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a report on Monday, April 21st. Finally, UBS Group dropped their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Qiagen has an average rating of “Hold” and a consensus price target of $47.83.

Qiagen Stock Performance

NYSE:QGEN opened at $42.10 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The stock has a market capitalization of $9.36 billion, a PE ratio of 117.23, a P/E/G ratio of 2.39 and a beta of 0.62. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The company has a fifty day moving average of $39.95 and a two-hundred day moving average of $41.72.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. As a group, research analysts forecast that Qiagen will post 2.26 earnings per share for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.